Actively Recruiting
Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
Led by Peking University Shenzhen Hospital · Updated on 2025-12-18
112
Participants Needed
1
Research Sites
48 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Pain management is a crucial part of general anesthesia surgery. Nociception monitoring can help anesthesiologists better titrate the use of intraoperative analgesic drugs, especially the opioid. 2. Although a variety of nociception monitoring devices have been developed to date, there is not a specific monitoring indicator that serves as the "gold standard" to objectively guide analgesic management in general anesthesia. 3. The MGRNOX index, which is derived from electroencephalogram (EEG), is used to reflect the correlation between noxious stimuli and opioid analgesics in a state of general anesthesia by converting and quantifying the EEG signals collected by the instrument. However, no studies have so far verified the effect of the MGRNOX index-guided analgesic management of general anesthesia on the consumption of opioids in patients. 4. This study aims to explore the effect of MGRNOX index-guided general anesthesia on opioid consumption in patients undergoing laparoscopic cholecystectomy and the primary hypothesis of our study is that using the MGRNOX index to guide intraoperative pain management during general anesthesia can significantly reduce the consumption of remifentanil during the surgery.
CONDITIONS
Official Title
Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older and under 65 years
- American Society of Anesthesiologists (ASA) class I or II
- Scheduled for elective laparoscopic cholecystectomy under general anesthesia without epidural anesthesia, local blocks, or infiltration
You will not qualify if you...
- Pregnancy or breastfeeding
- Body mass index (BMI) 35 kg/m² or higher, or under 18.5 kg/m²
- Anticipated difficult airway
- Previous diagnosis of hypertension
- Drug or alcohol abuse in the past 6 months
- History of acute or chronic pain or routine preoperative use of opioid or non-opioid pain medications
- Peripheral or central nervous system disorders
- Psychiatric or neuropsychiatric conditions severely affecting cognition or use of psychotropic medications
- Allergy or intolerance to anesthetic agents
- Baseline mean arterial pressure (MAP) below 60 mmHg or above 120 mmHg
- Baseline heart rate below 45 bpm or above 90 bpm
- Severe untreated or ongoing cardiovascular, liver, kidney, or lung diseases
- Implanted pacemaker, chronic arrhythmia, or preoperative use of certain heart medications including anticholinergics, α2-adrenergic agonists, beta-1 blockers, or antiarrhythmics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Actively Recruiting
Research Team
T
Tao Luo, MD,PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here